Glycyrrhizin-Induced Pseudoaldosteronism Contributing to Decompensated Heart Failure With Preserved Ejection Fraction.
- 1Department of Cardiology, National Hospital Organization (NHO) Hiroshimanishi Medical Center, Otake, JPN.
Abstract
Glycyrrhizin, a component of licorice-containing medications such as Shakuyakukanzoto, can cause pseudoaldosteronism, characterized by hypokalemia and hypertension. However, its potential role in contributing to decompensated heart failure with preserved ejection fraction (HFpEF) has rarely been described. We report an elderly man who presented with dyspnea, peripheral edema, and pleural effusion after more than 10 years of Shakuyakukanzoto use. Electrocardiography showed atrial fibrillation, and echocardiography showed preserved left ventricular ejection fraction, left atrial enlargement, and echocardiographic findings suggestive of elevated left ventricular filling pressure, supporting the diagnosis of HFpEF. At presentation, we suspected pseudoaldosteronism based on the combination of hypokalemia, inappropriate renal potassium loss, and long-term use of Shakuyakukanzoto. Plasma renin activity and plasma aldosterone concentration were suppressed, supporting the diagnosis. Discontinuation of Shakuyakukanzoto, together with potassium supplementation, diuretic therapy, and spironolactone, resulted in resolution of hypokalemia and congestive findings and allowed reduction of antihypertensive medications. In conclusion, glycyrrhizin-induced pseudoaldosteronism may contribute to decompensated HFpEF through sodium and water retention in patients with limited cardiac tolerance to volume loading.
Related
- Dynamic change in soluble suppressor of tumorigenicity 2 (sST2) during acute decompensated heart failure with a reduced ejection fraction, and its mortality implications
- Advancing Heart Failure Classification Beyond Left Ventricular Ejection Fraction: Unsupervised Machine Learning Insights From the Japanese Nationwide Acute Decompensated Heart Failure Cohort: JROADHF
- Presumed right atrial myxoma causing mechanical inflow obstruction and a heart-failure-with-preserved-ejection-fraction–mimicking phenotype in a resource-limited setting: A case report
- Neutrophil-to-Lymphocyte Ratio Identifies a Pulmonary Vascular High-Risk Phenotype in Heart Failure with Preserved Ejection Fraction
- EASIX for Long-Term Prognostication in Hospitalized Heart Failure with Preserved Ejection Fraction: Incremental Value Beyond Clinical Risk Markers
BibTeX
@article{kurisu2026glycyrrhizininduced,
title = {{Glycyrrhizin-Induced Pseudoaldosteronism Contributing to Decompensated Heart Failure With Preserved Ejection Fraction.}},
author = {Satoshi Kurisu and Hitoshi Fujiwara},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116676},
url = {https://europepmc.org/article/MED/42923347},
note = {CC BY},
}
RIS
TY - JOUR
TI - Glycyrrhizin-Induced Pseudoaldosteronism Contributing to Decompensated Heart Failure With Preserved Ejection Fraction.
AU - Satoshi Kurisu
AU - Hitoshi Fujiwara
PY - 2026
DA - 2026/09/21
JO - Cureus
DO - 10.7759/cureus.116676
UR - https://europepmc.org/article/MED/42923347
AB - Glycyrrhizin, a component of licorice-containing medications such as Shakuyakukanzoto, can cause pseudoaldosteronism, characterized by hypokalemia and hypertension. However, its potential role in contributing to decompensated heart failure with preserved ejection fraction (HFpEF) has rarely been described. We report an elderly man who presented with dyspnea, peripheral edema, and pleural effusion after more than 10 years of Shakuyakukanzoto use. Electrocardiography showed atrial fibrillation, and echocardiography showed preserved left ventricular ejection fraction, left atrial enlargement, and echocardiographic findings suggestive of elevated left ventricular filling pressure, supporting the diagnosis of HFpEF. At presentation, we suspected pseudoaldosteronism based on the combination of hypokalemia, inappropriate renal potassium loss, and long-term use of Shakuyakukanzoto. Plasma renin activity and plasma aldosterone concentration were suppressed, supporting the diagnosis. Discontinuation of Shakuyakukanzoto, together with potassium supplementation, diuretic therapy, and spironolactone, resulted in resolution of hypokalemia and congestive findings and allowed reduction of antihypertensive medications. In conclusion, glycyrrhizin-induced pseudoaldosteronism may contribute to decompensated HFpEF through sodium and water retention in patients with limited cardiac tolerance to volume loading.
SN - 2168-8184
ER -